Your Cart Is Empty!
18/04/2015 | Philadelphia, PA, USA
The AACR Annual Meeting 2015 will highlight the latest, most exciting discoveries in every area of cancer research and will provide a unique opportunity for investigators from all over the world to meet, interact, and share their insights.
Cambridge, UK, and Boulder, CO, USA, 23rd March 2015: Horizon Discovery Group plc (LSE:HZD) (Horizon), the international life science company supplying research tools and services that power genomics research and the development of personalized medicines, and ArcherDX, Inc., a leader in Next Generation Sequencing (NGS) fusion detection, today announced they have signed an Original Equipment Manufacture (OEM) agreement that will see Horizon’s Reference Materials supplied as a standalone product alongside ArcherDX’s Archer™FusionPlex™ to aid customer validation of its ALK fusion assay kits.
In a first, an Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor IRESSA® (gefitinib) has received European label indication recommending the use of cell-free DNA from a blood sample when obtaining a tumour sample from a patient is not possible. This label change is based on the results of a collaboration between AstraZeneca and Qiagen.
IRESSA acts by blocking the transmission of signals involved in the growth and spread of tumors and is approved in 90 countries for the treatment of adult patients with locally advanced or metastatic Non Small Cell Lung Cancer (NSCLC).
Analyze the Impact of Formalin Treatment on your NGS Workflow
Send us a message
See our ordering page
Click here to register with us
More about shipping